A photocatalytic technology combining TiO2 semiconductors with proprietary electrocatalyst co-catalysts to produce hydrogen peroxide on demand using light. This green disinfectant offers a sustainable alternative for antimicrobial applications, eliminating the need for transported or stored chemicals.
This solution offers a photocatalytic platform for on-site, light-driven production of hydrogen peroxide using TiO2-based hybrid photocatalysts. By pairing a TiO2 semiconductor with proprietary electrocatalyst co-catalysts developed by the research group, the technology converts light energy into chemical energy, generating hydrogen peroxide as a green disinfectant. The produced hydrogen peroxide can be applied directly for antimicrobial purposes, such as killing bacteria, offering a sustainable and decentralized alternative to conventional chemical disinfection methods.
The approach addresses key challenges in disinfectant supply and sustainability by enabling local generation of hydrogen peroxide using sunlight or artificial light sources, reducing reliance on transported, stored, or industrially manufactured chemical disinfectants.
Core technology components:
Key features and benefits:
The electrocatalyst co-catalysts have already been synthesized and validated, demonstrating excellent catalytic activity and selectivity for hydrogen peroxide production. The next phase involves combining these co-catalysts with TiO2 via self-assembly, followed by testing of the hybrid photocatalysts for light-induced hydrogen peroxide generation and antimicrobial performance. Further work includes mechanistic studies and advanced characterization to understand performance origins. The technology is currently at an early-to-mid research and development stage, with components validated individually and integration testing underway.
The University of Adelaide was a comprehensive public research university in South Australia, with a city‑centre campus and specialised sites linking teaching, research and translation. Co‑location within Adelaide BioMed City placed teams beside the Royal Adelaide Hospital and SAHMRI, enabling clinical trials, while AIML at Lot Fourteen linked researchers to an innovation district. At the Waite Research Precinct, co‑located partners and infrastructure such as the Plant Accelerator supported industry‑engaged R&D. Research was backed by national funding, including the Australian Research Council and NHMRC. On January 5, 2026 it merged with the University of South Australia to form Adelaide University; these assets now operate within the new institution with dedicated tech transfer support.